2. Neuronal Signaling
  3. OGT
  4. Ac4-5SGlcNAc

Ac4-5SGlcNAc is an O-GlcNAc transferase (OGT) inhibitor. Ac4-5SGlcNAc converts intracellularly to UDP-5SGlcNAc, which competes with native UDP-GlcNAc (HY-148596) to block OGT catalytic activity, reduces cellular UDP-GlcNAc pools, and limits global protein O-GlcNAcylation. Ac4-5SGlcNAc reduces OGA levels via feedback, alters lectin signal intensities and glycan-related band masses. Ac4-5SGlcNAc can be used for the research of breast cancer.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Ac4-5SGlcNAc

Ac4-5SGlcNAc 화학구조

CAS No. : 67561-97-1

사이즈 재고
50 mg   견적 받기  
100 mg   견적 받기  
250 mg   견적 받기  

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

Ac4-5SGlcNAc Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • 순도&문서

  • References

  • 고객리뷰

제품 설명

Ac4-5SGlcNAc is an O-GlcNAc transferase (OGT) inhibitor. Ac4-5SGlcNAc converts intracellularly to UDP-5SGlcNAc, which competes with native UDP-GlcNAc (HY-148596) to block OGT catalytic activity, reduces cellular UDP-GlcNAc pools, and limits global protein O-GlcNAcylation. Ac4-5SGlcNAc reduces OGA levels via feedback, alters lectin signal intensities and glycan-related band masses. Ac4-5SGlcNAc can be used for the research of breast cancer[1][2][3].

IC50 & Target

Glycosyltransferase (OGT)[1]
In Vitro

Ac4-5SGlcNAc (50 μM; 24 h-5 days) potently reduces global O-GlcNAcylation in undifferentiated hESCs, downregulates OGA expression without altering hESC pluripotency or cell viability[1].
Ac4-5SGlcNAc (50 μM; daily from day -2 to day 11 of neural differentiation) reduces global O-GlcNAcylation and cellular UDP-GlcNAc levels in differentiating hESCs, induces compensatory changes in OGT and OGA expression, and does not disrupt core pluripotency or neural progenitor marker expression[1].
Ac4-5SGlcNAc (10-50 μM; daily from day -2 to day 11 of neural differentiation, 48 h prior to neural induction initiation) accelerates neuronal differentiation of H1, H7, and H9 hESCs, inducing premature expression of TUJ1 and MAP2, increasing neurite extension, and increasing the percentage of cells co-expressing these neuronal markers[1].
Ac4-5SGlcNAc (50 μM; daily from day -2 to day 11 of neural differentiation) upregulates neuronal differentiation and forebrain development-related genes in differentiating H1 hESCs, driving transcriptomic changes consistent with accelerated neuronal commitment[1].
Ac4-5SGlcNAc (50 μM; daily from day -2 to day 4 of neural differentiation) causes minor, transient changes to cell surface glycosylation in hESCs, with no detectable differences once neural induction is underway[1].
Ac4-5SGlcNAc (50 μM; 2-24 h) inhibits global O-GlcNAcylation in CHO cells in vitro in a dose-dependent manner, with a maximal effect at 50 μM over 24 h and observable reduction starting at 4 h[2].
Ac4-5SGlcNAc (50 μM; 24 h) modulates established OGT inhibition biomarkers in CHO cells, including a Nup62 mass shift, sOGT accumulation, and reduced OGA levels[2].
Ac4-5SGlcNAc (50 μM; 24 h) inhibits global O-GlcNAcylation in CHO, HEK-293, HeLa, and D283-Med cells[2].
Ac4-5SGlcNAc (50 μM; 24 h) alters specific cell surface glycan structures in CHO cells, as detected by reduced binding of lectins PHA-E, Jacalin, and LCA, while not grossly perturbing glycans recognized by several other tested lectins[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ac4-5SGlcNAc Related Antibodies

Western Blot Analysis[1]

Cell Line: undifferentiated human embryonic stem cells (hESCs)
Concentration: 50 μM
Incubation Time: 24 h; 5 days
Result: Abrogated the majority of detectable protein O-GlcNAcylation after 24 h treatment.
Caused a time-dependent decrease in O-GlcNAc levels for up to 3 days, after which levels started to increase following 5 days treatment.
Decreased OGA protein expression over the 5-day period.
Left OCT4 expression (a pluripotency marker) unaffected.
Caused no changes in cell morphology or proliferation.

Western Blot Analysis[1]

Cell Line: hESCs undergoing neural differentiation
Concentration: 50 μM
Incubation Time: daily from day -2 to day 11 of neural differentiation
Result: Maintained consistently lower global O-GlcNAcylation levels than DMSO-treated controls while preserving the oscillation pattern characteristic of neural differentiation.
Decreased OGA protein expression and increased OGT protein expression (compensatory changes).
Left OCT4 and PAX6 expression unchanged relative to controls.
Reduced UDP-GlcNAc levels significantly across all days of differentiation compared to DMSO-treated cells.

Immunofluorescence[1]

Cell Line: H1, H7, H9 hESCs undergoing neural differentiation
Concentration: 10 μM; 50 μM
Incubation Time: daily from day -2 to day 11 of neural differentiation
Result: Accelerated TUJ1 expression compared to controls after 50 μM treatment for 48 h before neural induction.
Caused premature TUJ1 expression as early as day 8 and greater neurite extension via immunofluorescence when 50 μM was added daily from day -2 to day 11.
Enabled detection of TUJ1 and MAP2 co-expression in H1, H7, and H9 hESC lines by day 11.
Caused a 10-fold difference in TUJ1/MAP2 co-expression between treated and DMSO-treated cells by day 6; by day 11, 3% of treated cells co-expressed both markers, compared to 1% of control cells.
Induced similar accelerated neuronal marker expression with 10 μM treatment.

Western Blot Analysis[2]

Cell Line: Chinese hamster ovary (CHO) cells
Concentration: 50 μM
Incubation Time: 24 h
Result: Caused Nup62 to shift to a lower molecular weight, consistent with loss of O-GlcNAc residues.
Resulted in accumulation of the short isoform of OGT (sOGT) while full-length ncOGT levels remained unchanged.
Decreased levels of OGA (O-GlcNAcase).

Western Blot Analysis[2]

Cell Line: Chinese hamster ovary (CHO) cells, HEK-293 cells, HeLa cells, D283-Med cells
Concentration: 50 μM
Incubation Time: 24 h
Result: Reduced global O-GlcNAc levels in all four tested mammalian cell lines.
분자량

405.42

화학식

C16H23NO9S
CAS No.
SMILES

CC(O[C@H]1[C@@H]([C@H](S[C@@H]([C@@H]1NC(C)=O)OC(C)=O)COC(C)=O)OC(C)=O)=O
선적

Room temperature in continental US; may vary elsewhere.
보관

Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Ac4-5SGlcNAc Related Classifications

  • 몰농도 계산기

  • 농도 희석 계산기

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Ac4-5SGlcNAc67561-97-1OGTO-linked N-acetylglucosaminyltransferaseO-GlcNAc transferasehESCsCHO cellsUDP-5SGlcNAcO-GlcNAcasebreast cancer cellUDP-GlcNAchuman embryonic stem cellOGAInhibitorinhibitorinhibit

최근 본 상품:

온라인 문의

Your information is safe with us. * Required Fields.

상품명

  

Requested Quantity *

고객명 *

 

호칭

메일주소 *

 

전화번호 *

Department

 

회사명 *

City

도

Country or Region *

      

비고

대량구매 문의

Inquiry Information

상품명:
Ac4-5SGlcNAc
Cat. No.:
HY-149552
수량:
MCE Japan Authorized Agent:

고객리뷰

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

상품명

  

Lot #

고객명 *

 

메일주소 *

전화번호

 

Department *

회사명 *

 

Country or Region *

비고

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.